Vaccine (mRNA vaccine) · Immune activation · developed by BioNTech
BNT165d is a multi-antigen RNA-based vaccine given by intramuscular injection for active immunization against malaria. It is studied in malaria, including falciparum malaria.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06069544 | Phase 1/2 | Malaria | Completed | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Malaria
Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →